Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

Published:2012-08-03 Issue:1 Volume:62 Page:137-147
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Sheikh Nadeem A.,Petrylak Daniel,Kantoff Philip W.,dela Rosa Corazon,Stewart Frances P.,Kuan Ling-Yu,Whitmore James B.,Trager James B.,Poehlein Christian H.,Frohlich Mark W.,Urdal David L.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-012-1317-2

Reference36 articles.

1. Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10:580–593. doi: 10.1038/nri2817

2. Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854

3. Neelapu SS, Kwak LW, Kobrin CB et al (2005) Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11:986–991. doi: 10.1038/nm1290

4. Slingluff CL Jr, Petroni GR, Olson WC et al (2009) Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036–7044. doi: 10.1158/1078-0432.CCR-09-1544

5. Goldstein NS (2002) Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 117:471–477

Cited by 217 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering W/O/W pickering emulsion for the enhanced antigen delivery and immune responses;Particuology;2024-09

2. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy;Future Oncology;2024-08-05

3. Cancer Vaccines: Another Aspect to Immunotherapy;Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 );2024-07-07

4. Cancer mRNA vaccines: clinical advances and future opportunities;Nature Reviews Clinical Oncology;2024-05-17

5. New approaches and prospects of immunotherapy and gene therapy for prostate cancer;Journal of Translational Genetics and Genomics;2024-03-29